Quarterly report pursuant to Section 13 or 15(d)

DESCRIPTION OF BUSINESS (Details Narrative)

v3.21.2
DESCRIPTION OF BUSINESS (Details Narrative) - $ / shares
6 Months Ended
Jun. 15, 2021
Oct. 31, 2021
Apr. 30, 2021
Subsidiary, Sale of Stock [Line Items]      
Description of novel products   The Company’s primary focus is Alzheimer’s disease (“Alzheimer’s”). With two current and future product candidates, Alzamend aims to bring treatments and/or potential cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc. (the “Licensor”), and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license with Licensor  
Common stock, par value (in dollars per share)   $ 0.0001 $ 0.0001
Stock Issued During Period, Shares, New Issues   212,500  
Series A Preferred Stock [Member]      
Subsidiary, Sale of Stock [Line Items]      
Preferred stock, outstanding   750,000 750,000
IPO [Member]      
Subsidiary, Sale of Stock [Line Items]      
Stock Issued During Period, Shares, New Issues 2,875,000    
[custom:PublicOfferingPrice] $ 5.00    
IPO [Member] | Series A Preferred Stock [Member]      
Subsidiary, Sale of Stock [Line Items]      
Preferred stock, outstanding   15,000,000  
IPO [Member] | Digital Power Lending [Member]      
Subsidiary, Sale of Stock [Line Items]      
Stock Issued During Period, Shares, Other 2,000,000